Single molecule binding of a ligand to a G-protein-coupled receptor in real time using fluorescence correlation spectroscopy, rendered possible by nano-encapsulation in styrene maleic acid lipid particles†

Rachael L. Grime, a,b Joelle Goulding, a,b,c Romez Uddin, b,d Leigh A. Stoddart, b,c Stephen J. Hill, b,c David R. Poyner, d Stephen J. Briddon b,c and Mark Wheatley b,c

The fundamental importance of membrane proteins in cellular processes has driven a marked increase in the use of membrane mimetic approaches for studying and exploiting these proteins. Nano-encapsulation strategies which preserve the native lipid bilayer environment are particularly attractive. Consequently, the use of poly(styrene co-maleic acid) (SMA) has been widely adopted to solubilise proteins directly from cell membranes by spontaneously forming “SMA Lipid Particles” (SMALPs). G-protein-coupled receptors (GPCRs) are ubiquitous “chemical switches”, are central to cell signalling throughout the evolutionary tree, form the largest family of membrane proteins in humans and are a major drug discovery target. GPCR-SMALPs that retain binding capability would be a versatile platform for a wide range of downstream applications. Here, using the adenosine A2A receptor (A2AR) as an archetypical GPCR, we show for the first time the utility of fluorescence correlation spectroscopy (FCS) to characterise the binding capability of GPCRs following nano-encapsulation. Unbound fluorescent ligand CA200645 exhibited a monophasic autocorrelation curve (dwell time, $r_D = 68 \pm 2 \mu s$; diffusion coefficient, $D = 287 \pm 15 \mu m^2 s^{-1}$). In the presence of A2aR-SMALP, bound ligand was also evident ($r_D = 625 \pm 23 \mu s$; $D = 30 \pm 4 \mu m^2 s^{-1}$). Using a non-receptor control (ZipA-SMALP) plus competition binding confirmed that this slower component represented binding to the encapsulated A2aR. Consequently, the combination of GPCR-SMALP and FCS is an effective platform for the quantitative real-time characterisation of nano-encapsulated receptors, with single molecule sensitivity, that will have widespread utility for future exploitation of GPCR-SMALPs in general.

Introduction

Membrane proteins have evolved to function within the unique environment of the hydrated membrane bilayer, which locates proteins in close association with lipids and provides lateral pressure. Extracting membrane proteins from this bilayer for purification and characterisation has, until recently, universally required detergents. This detergent solubilisation strips away closely-associated lipids, removes lateral pressure and perturbs the protein conformation, resulting in protein instability in the detergent micelle.1,2 This is particularly problematic for highly dynamic membrane proteins such as G-protein-coupled receptors (GPCRs).3 GPCRs all share a common protein architecture of a bundle of seven transmembrane helices and adopt a wide spectrum of conformational states in executing their cell signalling role.4 They are found in organisms throughout the phylogenetic tree including humans, fish, insects, plants, slime-moulds and viruses (but not bacteria) and form the largest class of ‘chemical switches’ in biology. They transduce signals from chemical messengers acting on a cell, such as hormones and neurotransmitters,

†Electronic supplementary information (ESI) available: Supplementary figures (Fig. S1–S3). See DOI: 10.1039/d0nr01060j
into biochemical changes within the cell via activation of intracellular signalling cascades. As a result, they regulate almost every physiological process. Consequently, GPCRs are the largest class of membrane proteins in the human genome (with >800 receptors). Furthermore, they are very important to the pharmaceutical industry as they are the therapeutic target of 30–40% of clinically-prescribed drugs.6,7

In recent years, a detergent-free method has been developed for solubilising membrane proteins using poly(styrene co-maleic acid) (SMA). SMA spontaneously incorporates into membranes to generate nanoscale sections of the lipid bilayer as discs (~10 nm in diameter) containing encapsulated membrane protein, referred to as styrene maleic acid lipid particles (SMALPs).8–12 Nanoscale encapsulation of GPCRs in SMALPs (GPCR-SMALPs) has potential utility for facilitating a wide range of downstream approaches such as; supporting biophysical10,11 and structural studies,13,14 a platform for discovery of GPCR-targeted therapeutic antibodies using phage display libraries, and for high-throughput screening in drug discovery following immobilisation of GPCR-SMALPs on surface plasmon resonance (SPR) chips.3 In addition, there is potential for harnessing the exquisite ligand-recognition capability of GPCR-SMALPs into bespoke molecular detection devices using synthetic biology. A pre-requisite to all of these applications is establishing that the ligand-binding capability of the encapsulated GPCR is preserved in the GPCR-SMALP.

It is noteworthy that in recent years there has been a rapid increase in the design of fluorescent ligands for quantitative characterisation of binding to GPCRs.15–17 This development has enabled fluorescence correlation spectroscopy (FCS) to be applied to studying GPCRs in cells.18 FCS is a quantitative technique with single molecule sensitivity which uses confocal optics and a high numerical aperture objective lens to generate a small, defined illumination volume (~0.25 fL). As a fluorescent species moves through the detection volume, fluctuations in fluorescent intensity are recorded in real time. Statistical analysis of the time-dependency of these fluctuations using autocorrelation analysis allows the average dwell time of the fluorescent moiety within the detection volume to be determined.18 Additionally, the amplitude of the autocorrelation curve is inversely proportional to the average concentration of fluorescent particles in the detection volume. This makes FCS particularly sensitive for investigating low concentrations of particles, a definite advantage for studying low-abundance targets such as GPCRs. A property of FCS is that the dwell time ($\tau_0$) is proportional to the cube root of the molecular mass, so a doubling of mass only increases $\tau_0$ by 1.3-fold. When two fluorescent species are present in the detection volume simultaneously, they can only be resolved by FCS if the difference in their masses is large enough to yield a difference in $\tau_0$ values of at least 1.6-fold.19 Consequently, this combination of fluorescent probes and FCS has proven to be highly effective for studying GPCRs embedded in the surface of live cells.20–24 In this study we establish that nano-encapsulation of a GPCR within a SMALP provides the required size differential to make this a versatile strategy for quantitative analysis of ligand : GPCR complex formation by FCS. In addition, it is likely that the utility of FCS is not restricted to SMALPs but could apply more widely to GPCRs embedded in nanoscale discs of membrane irrespective of the method of encapsulation.

The adenosine A2A receptor (A2AR) is a typical GPCR with a well-defined pharmacology. It belongs to a family of four GPCRs (A1R, A2AR, A2BR, A3R) that mediate the actions of adenosine and are attractive drug targets.25 The A2AR regulates the release of the neurotransmitters dopamine and glutamate in the brain, regulates blood flow to cardiac muscle and is the target for the most widely used psychoactive drug – caffeine, which blocks this receptor.26 In this study, utilising the human A2AR as the GPCR, we demonstrate for the first time, the application of FCS to provide quantitative data on the binding characteristics of a GPCR that has been purified embedded within the nanoscale bilayer of the SMALP. This SMALP strategy ensures that the native lipid in close-association with the receptor protein has never been disrupted by detergent at any stage. Our study not only establishes the utility of employing FCS for characterising GPCR-SMALPs, but opens up the possibility of exploiting high-throughput solution-based FCS,27 and highlights the potential for identifying novel fluorescent ligands targeted to specific GPCRs. In recent years, SMA has been widely used to solubilise structurally-diverse membrane proteins from a wide range of species (including bacteria, yeast, plants, insect cells and mammalian cells). The application of SMA for studying GPCRs and other membrane proteins is increasing rapidly as the utility of SMALPs becomes ever more apparent. Furthermore, ‘second-generation’ SMA-like polymers have already been reported that possess different properties to SMA, so the field is still expanding.28–30 The application of FCS as a quantitative, real-time technique, with single molecule sensitivity will have widespread utility for the development of downstream applications of SMALPs as an investigation platform in this growing field.

**Experimental**

**Materials**

CA200645 was supplied by HelloBio (Bristol, UK). SMA2000 anhydride was from Cray Valley (UK). ZM241385 {4-[(2-[7-amino-2-(2-furyl)]|1,2,4|triazolol[2,3-α]|1,3,5|triazin-5yl amino] ethyl}phenol was purchased from Tocris.

**Human A2A R expression**

Human A2AR was expressed in *Pichia pastoris* as described previously.11 Prior to SMA-extraction, cells were disrupted following suspension in breaking buffer (50 mM sodium-phosphate buffer, 100 mM NaCl, 5% glycerol, EDTA-free protease inhibitor, pH 7.5, 4 °C) by 3–5 passes using an Avestin-C3 cell-disrupter. Unbroken cells and debris were removed by centrifugation (5000g, 10 min, 4 °C). The A2AR-expressing membrane fraction was then sedimented (100 000g, 60 min, 4 °C) and re-suspended to 80 mg mL$^{-1}$ (wet weight) in extraction buffer.
(300 mM NaCl, 20 mM HEPES, pH 7.5). Membranes were stored at −80 °C until needed.

**Generation of A2AR-SMALPs**

SMA was prepared from SMA anhydride and used to solubilise A2AR from membranes as described previously. Briefly, A2AR-expressing membrane preparations were thawed on ice, and an equal volume of 2× SMA buffer (5% w/v SMA, 300 mM NaCl, 20 mM HEPES, EDTA-free protease inhibitor, pH 7.5) added to yield a final concentration of 40 mg mL⁻¹ (wet weight) in 2.5% (w/v) SMA. Following gentle agitation for 1 h at room temperature, non-solubilised material was removed by centrifugation (100 000 g, 60 min, 4 °C) to yield a supernatant containing A2AR-SMALPs.

**Purification of A2AR-SMALPs**

All purification steps were carried out at 4 °C. The A2AR-SMALP supernatant was incubated with ~1 mL Ni²⁺-NTA resin, overnight on an end-on-end rotator. The column was washed with 20 column volumes (cv) of wash buffer (300 mM NaCl, 20 mM HEPES, 25 mM imidazole, EDTA-free protease inhibitor pH 7.5). Elution of A2AR-SMALP was achieved with 10 cv of elution buffer (300 mM NaCl, 20 mM HEPES, 250 mM imidazole, EDTA-free protease inhibitor pH 7.5). Elution fractions were pooled, buffer-exchanged into assay buffer (300 mM NaCl, 20 mM HEPES, pH 7.5) and concentrated using spin-concentrators (10 kDa cut-off). Concentrations of purified A2AR-SMALP were determined using SDS-PAGE and densitometric analysis against protein standards in ImageJ. Final concentrations ranged between 0.2–1 mg mL⁻¹.

**FCS protocols**

Solution-based FCS was performed essentially as described previously. FCS measurements were carried out on Nunc Lab-Tek 8-well chambered #1.0 cover-glasses (Thermo Scientific, UK), using a ZEISS LSM510 Confocor3 using 633 nm excitation (0.5–1 kW cm⁻²), with emission collected through an LP650 filter. The confocal volume was placed 200 μm above the surface of the coverslip. Cy5 NHS ester (Amersham Pharmacia Bioscience) was prepared in high performance liquid chromatography grade water (Chromasolv, Sigma-Aldrich, UK). As Cy5 has a known diffusion coefficient \(D = 3.16 \times 10^{-18} \text{m}^2 \text{s}^{-1}\), it was employed as the standard fluorescent dye (10 nM and 500 nM) to calculate the confocal volume dimensions using eqn (1), where \(V = \text{volume (mL)}\), \(\theta_1\) is the radius of the confocal volume, determined from \(\theta_1 = \frac{4D \tau_{01}}{3}\), where \(D\) and \(\tau_{01}\) are the diffusion coefficient and dwell time of Cy5, respectively. \(\theta_2\) represents half the height of the confocal volume and is calculated by multiplying \(\theta_1\) by the structural parameter (S). Calibration readings were taken on each day’s experiments. FCS measurements were performed in a final assay volume of 200 μL. A2AR-SMALPs were incubated with CA200645 (25 nM), in the presence or absence of varying concentrations of ZM241385 as stated. Equilibrium was established at 30 min and four read-times, each of 10 s, were employed to record time-dependent fluctuations in fluorescent intensity.

**Data analysis**

Autocorrelation analysis was performed using Zeiss AIM 4.2 software. Cy5 calibration data were used to calibrate the detection volume as previously described. Experimental data were fitted to eqn (2), where \(N = \text{particle number, } f_i = \text{fraction of } \tau_i\) component, \(\tau_{0i}\) is dwell time of \(\tau_i\) component, \(S = \text{structure parameter (ratio of diameter to height of volume). A 1-component or 2-component 3-D diffusion model was used incorporating a triplet state component fitted using a pre-exponential. Fit quality was assessed on residuals to the fit. For 2-component fits, the first component \((\tau_{01})\), representing free ligand, was fixed during the fitting process to the value determined for CA200645 alone, and the second component \((\tau_{02})\) represented bound ligand. The concentrations of free and bound components were then calculated directly from their relative contributions to the amplitude of the autocorrelation function. Specific binding was determined using eqn (3). Total binding was defined as \(N(\tau_{01})\) (nM) as calculated from the autocorrelation analysis curve for A2AR-SMALPs in the absence of competing ligand. Non-specific binding was defined as \(N(\tau_{02})\) (nM) calculated from the autocorrelation analysis curve for A2AR-SMALPs in the presence of saturating competing ligand. The affinity \((pK_i)\) of ZM241385 binding to the A2AR-SMALP was determined from the IC₅₀ value of the ZM241385 competition binding curve following correction for occupancy by the tracer ligand CA200645. The Stokes–Einstein equation (eqn (4)) was used to probe the relationship between the diffusion time of the SMALP nanoparticle and its hydrodynamic radius; where \(D = \text{diffusion coefficient, } k_b = \text{Boltzmann’s constant, } T = \text{temperature (K), } \eta = \text{dynamic viscosity and } r = \text{radius of the particle. Pooled data are presented as the mean ± s.e.m. for 3, or 4, independent preparations of A2AR-SMALP. Significance (p < 0.05) was determined by Student’s paired t-test.}

\[
V = \pi \cdot \theta_1^2 \cdot \theta_2 \quad (1)
\]

\[
G(r) = 1 + \frac{1}{N} \sum_{i=1}^{\infty} f_i \cdot \left(1 + \frac{\tau}{\tau_{0i}}\right)^{-1} \left[1 + \frac{\tau}{S^2 \cdot \tau_{0i}}\right]^{-1} \quad (2)
\]

\[
\text{Specific binding} = \text{Total binding} - \text{Non-specific binding} \quad (3)
\]

\[
D = \frac{k_b T}{6\pi\eta r} \quad (4)
\]

**Results and discussion**

**A2AR-SMALPs provides a platform for FCS**

The A2AR-SMALPs were generated using SMA (2.5% w/v) to extract the receptors from A2AR-expressing membranes into SMALPs, followed by purification of the A2AR-SMALPs as previously described (Fig. S1†). The current studies utilized the
fluorescent ligand CA200645, which comprises the adenosine receptor antagonist xanthine amine congener (XAC) linked to a red BODIPY630/650 fluorophore via a β-alanine linker.\textsuperscript{13} CA200645 is a high affinity ligand for both the A\textsubscript{1}R and A\textsubscript{3}R subtypes\textsuperscript{13–15} and was used previously as the tracer ligand to investigate dimerization and allosteroy of A\textsubscript{2}AR in whole live cells using FCS.\textsuperscript{20} Given that CA200645 is derived from the non-selective adenosine receptor antagonist XAC, it was hypothesized that CA200645 would not be A\textsubscript{1}R/A\textsubscript{3}R-selective and would also bind to the A\textsubscript{2}AR. Subsequent pharmacological characterization established that CA200645 bound to the A\textsubscript{2}AR (ZM241385, 36 1 µM). Specific binding varied between 20 ± 11% (mean ± s.e.m., n = 3; Fig. S2\textdagger). The initial stage of the investigation was to optimize the concentration of CA200645 for solution-based FCS, to ensure that specific binding to the A\textsubscript{2}AR encapsulated in the SMALP concentration of CA200645 for solution-based FCS, to ensure characterization established that CA200645 bound to the A\textsubscript{2}AR (ZM241385, 36 1 µM). Specific binding varied between 20 ± 11% (mean ± s.e.m., n = 3; Fig. S2\textdagger).

The initial stage of the investigation was to optimize the concentration of CA200645 for solution-based FCS, to ensure that specific binding to the A\textsubscript{2}AR encapsulated in the SMALP was high compared to non-specific binding. The CA200645 concentration was varied between 5–300 nM and non-specific binding determined in each case by adding a saturating concentration of a non-fluorescent competing A\textsubscript{2}AR ligand (ZM241385, 36 1 µM). Specific binding varied between 20 ± 11% and 70 ± 12% of total binding (Fig. 1), with 25 nM CA200645 being used in all subsequent experiments. A data-collection time of 10 s was routinely employed which provided ample fluorescent fluctuation data for autocorrelation analysis.

The initial FCS experiments were performed with CA200645 alone in assay buffer to determine the characteristics of the free ligand. Fluorocounts in fluorescence intensity for CA200645 over time are shown in Fig. 2a. Autocorrelation analysis of these fluctuations revealed a monophasic autocorrelation curve (Fig. 2b) with an average dwell time (τ\textsubscript{D}) of the fluorescent moiety within the detection volume of 68 ± 2 µs and a diffusion coefficient D = 287 ± 15 µm\textsuperscript{2} s\textsuperscript{-1} (mean ± s.e.m., n = 4) with residuals (Fig. 2c) confirming that there was no systematic deviation in the fitted curve. The experiments were then repeated using CA200645 in the presence of A\textsubscript{2}AR-SMALP. The fluorescence intensity fluctuations for CA200645 + A\textsubscript{2}AR-SMALP are shown in Fig. 2d. Analysis of these fluctuations revealed that the autocorrelation curve for CA200645 was significantly altered by the addition of A\textsubscript{2}AR-SMALP. In contrast to the monophasic curve observed for ligand alone (Fig. 2b), the autocorrelation curve for CA200645 + A\textsubscript{2}AR-SMALP was clearly biphasic (Fig. 2e) exhibiting fast and slow diffusing components (τ\textsubscript{D1} and τ\textsubscript{D2}, respectively) with the residuals (Fig. 2f) confirming that there was no systematic deviation in the fitted curve. The faster diffusing component exhibited a dwell-time (τ\textsubscript{D1}) consistent with the free ligand (Fig. 2b). The slower component had an average dwell-time (τ\textsubscript{D2}) for CA200645 of 625 ± 23 µs and a diffusion coefficient D = 30 ± 4 µm\textsuperscript{2} s\textsuperscript{-1} (mean ± s.e.m., n = 4). As a control, A\textsubscript{2}AR-SMALPs alone were shown to have no detectable auto-fluorescence (Fig. S3\textdagger).

Characterization of the slower diffusing component (τ\textsubscript{D2})

The logical explanation for the emergence of the slower diffusing component in the presence of A\textsubscript{2}AR-SMALP is that the ligand was binding to the receptor in the A\textsubscript{2}AR-SMALP and that both free and bound CA200645 were being detected by FCS simultaneously as τ\textsubscript{D1} and τ\textsubscript{D2} respectively (Fig. 2e). Indeed, the simultaneous determination of the free ligand concentration precisely where the binding event is occurring is a particular benefit of FCS for characterising ligand : GPCR complexes. The binding of CA200645 to the A\textsubscript{2}AR-SMALP could have been specific binding to the encapsulated GPCR or could possibly have been non-specific binding caused by partitioning of CA200645 into the lipid bilayer of the SMALP or interaction of the ligand with the SMA polymer surrounding the SMALP. The pharmacological properties of the receptor were exploited to establish the nature of the binding. A competing A\textsubscript{2}AR-selective ligand ZM241385 was used at a saturating concentration. This would fully occupy the available A\textsubscript{2}AR binding sites and prevent binding of CA200645 but would not prevent any non-specific binding site of the receptor and prevented CA200645 binding. In contrast, there was no effect of ZM241385 (1 µM) in control experiments performed using different membrane protein encapsulated in a SMALP (ZipA, derived from Escherichia coli). ZipA-SMALP showed a lower particle number than A\textsubscript{2}AR-SMALP consistent with low CA200645 binding expected in the absence of receptor (Fig. 3).

A range of ZM241385 concentrations between 10\textsuperscript{-12} M–10\textsuperscript{-6} M was used to construct a competition curve for ZM241385 binding to the nano-encapsulated A\textsubscript{2}AR using FCS with CA200645 as tracer ligand (Fig. 4). From these data, the affinity (pK\textsubscript{D}) of ZM241385 for the A\textsubscript{2}AR-SMALP was calculated as 8.2 ± 0.5 (mean ± s.e.m., n = 3). This is not significantly different to
The reported affinity of ZM241385 binding to A2AR in the original membranes ($pK_i = 7.95 \pm 0.45$).\(^{11}\)

The diffusion coefficient of the CA200645:A2AR-SMALP complex ($D = 30 \pm 4 \mu \text{m}^2 \text{s}^{-1}$) was used to estimate the hydrodynamic radius of the A2AR-SMALP as calculated by the Stokes–Einstein equation (eqn (4)), with the caveat that SMALPs are disc-shaped rather than spherical. The resulting values of 7–9 nm were consistent with the published values for the SMALP diameter of c.10 nm determined by a wide range of biophysical techniques, including small angle neutron scattering (SANS), electron microscopy (EM), attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR), differential scanning calorimetry (DSC) and nuclear magnetic resonance spectroscopy (NMR).\(^{10,37}\)

Numerous applications of FCS with GPCR-SMALPs can be envisaged. For example, allosteric modulators of GPCRs bind to sites on the receptor discrete from the ‘classical’ ligand binding site and are of current interest to the pharmaceutical industry as they have therapeutic potential for ‘tuning’ receptor signalling (up or down).\(^{38}\) The size differential between

---

**Fig. 2** FCS analysis of CA200645 binding to purified A2AR-SMALP. (a) Fluctuations in fluorescent intensity with CA200645 alone. (b) Autocorrelation curve for CA200645 alone, fitted to a single-component diffusion model. (c) Deviation of data for CA200645 alone from the fitted curve. (d) Fluctuations in fluorescent intensity with CA200645 + A2AR-SMALP. (e) Autocorrelation curve for CA200645 + A2AR-SMALP fitted to a two-component diffusion model, in which the first component ($\tau_D1$) was fixed to a three-dimensional diffusion rate of the free-ligand in solution. (f) Deviation of data for CA200645 + A2AR-SMALP from the fitted curve.
GPCR-SMALPs and fluorescent ligands is sufficiently large that FCS will be a useful tool in the future for investigating potential allosteric modulators as it is compatible with a very wide range of modulator sizes from small molecules to therapeutic antibodies. Of course other approaches for nano-encapsulation of GPCRs, such as reconstituted lipid nanodiscs stabilised by an annulus of membrane scaffolding proteins\textsuperscript{28} or the use of recently-reported SMA-like polymers\textsuperscript{28-30} may also be compatible with characterisation using FCS.

The application of SMALPs to studying membrane proteins is expanding rapidly\textsuperscript{40} and recently SMALPs have been used to obtain high resolution structures of membrane proteins; including crystallisation of the proton pump bacteriorhodopsin transferred from SMALPs into lipidic cubic phase for \textit{in meso} crystallisation\textsuperscript{13} and the cryo-EM structure of bacterial alternative complex III in a super-complex with cytochrome oxidase encapsulated in a SMALP\textsuperscript{44}. Combining the technologies of fluorescence imaging and SMALP-solubilisation for studying membrane proteins is becoming increasingly versatile. For example, using proteins fluorescently labelled \textit{via} introduced unnatural amino acids to enable single-molecule fluorescence studies and using FCS to confirm the existence of dimers of the transporter protein ABCG2 and its interaction with substrate.\textsuperscript{41,42} This expanding utility of SMALPs has been the driver for developing new amphiphatic co-polymers that retain the ability of SMA to solubilise membrane proteins but exhibit different physico-chemical characteristics to SMA. For example, styrene-co-maleimide (SMI) is positively-charged and retains functionality at acidic pH, in contrast to the negative charge and alkaline working range of SMA;\textsuperscript{28} styrene maleimide quarterernary ammonium (SMA-QA) forms relatively large molecules of PIP2 whereas PIP2 did not stabilise coupling between plasma membrane of \textit{P. pastoris} and other mini-Gs subunits.\textsuperscript{49} Although the plasma membrane of \textit{P. pastoris} differs from that of mammalian cells, notably in substitution of cholesterol by ergosterol, the major classes of phospholipids are similar and the \textit{A}_{2}\textit{AR} was pharmacologically active.\textsuperscript{50} Furthermore, phospholipids in SMALPS can also be exchanged,\textsuperscript{51} which offers opportunities in the future for modifying the lipid composition following isolation of GPCRs in SMALPs. Overall, the preservation of native lipid encapsulated in GPCR-SMALPs combined with the
advantages of FCS described above, establishes a versatile platform for investigating ligand:GPCR interactions specifically, and membrane protein interactions in general, in the future.

Conclusions

Nanodisc technology is becoming widely adopted as a membrane protein solubilisation strategy due to the benefits provided by SMALPs over other solubilisation approaches. Proteins are directly solubilised from membranes with preservation of the annular lipids thereby maintaining the native environment of the encapsulated protein. This is a notable advantage for research focusing on the large GPCR family of membrane proteins which constitute the primary therapeutic target for drug discovery.6

Nano-encapsulation of one of these GPCRs (the A2AR) into SMALPs allowed us to report the first use of solution-based FCS to investigate the ligand binding capability of the receptor within the nanodisc particle in real time. Our study established that GPCR-SMALP used in combination with FCS is a powerful approach for characterising ligand:receptor complexes in a nano-scale native environment. It is anticipated that given the versatility and general utility of our strategy, it can be applied to the quantitative investigation of a wide range of target receptors plus their cognate ligands, modulators and interacting protein partners in the future.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by funding from the Biotechnology and Biological Sciences Research Council (BBSRC: BB/R016615/1 and BB/R016755/1) to MW and DRP and the Medical Research Council (MRC: MR/N020081/1) to SJH and SJB. RLG was supported by a BBSRC-MIBTP award to RLG and MW.

References

1 J.-L. Popot, Annu. Rev. Biochem., 2010, 79, 737–775.
2 M. Le Maire, P. Champeil and J. V. Moller, Biochim. Biophys. Acta, 2000, 1508, 86–111.
3 M. Wheatley, J. Charlton, M. Jamshad, S. J. Routledge, S. Bailey, P. J. La-Borde, M. T. Azam, R. T. Logan, R. M. Bill, T. R. Dafforn and D. R. Poyner, Biochem. Soc. Trans., 2016, 44, 619–623.
4 A. J. Venkatakrishnan, X. Deupi, G. Lebon, F. M. Heydenreich, T. Flock, T. Miljus, S. Balaji, M. Bouvier, D. B. Veprintsev, C. G. Tate, G. F. Schertler and M. M. Babu, Nature, 2016, 536, 484–487.
5 M. Wheatley, D. Wootten, M. T. Conner, J. Simms, R. Kendrick, R. T. Logan, D. R. Poyner and J. Barwell, Br. J. Pharmacol., 2012, 165, 1688–1703.
6 A. S. Hauser, M. M. Atwood, M. Rask-Andersen, H. B. Schiöth and D. E. Gloriam, Nat. Rev. Drug Discovery, 2017, 16, 829–842.
7 K. Sriram and P. A. Insel, Mol. Pharmacol., 2018, 93, 251–258.
8 T. J. Knowles, R. Finka, C. Smith, Y. P. Lin, T. Dafforn and M. Overduin, J. Am. Chem. Soc., 2009, 131, 7484–7485.
9 C. Vargas, R. C. Arenas, E. Frotscher and S. Keller, Nanoscale, 2015, 7, 20685–20696.
10 M. Jamshad, V. Grimard, I. Idini, T. J. Knowles, M. R. Dowle, N. Schofield, P. Sridhar, Y. Lin, R. Finka, M. Wheatley, O. R. T. Thomas, R. E. Palmer, M. Overduin, C. Govaerts, J.-M. Roysschaert, K. J. Edler and T. R. Dafforn, Nano Res., 2015, 8, 774–789.
11 M. Jamshad, J. Charlton, Y.-P. Lin, S. J. Routledge, Z. Bawa, T. J. Knowles, M. Overduin, N. Dekker, T. R. Dafforn, R. M. Bill, D. R. Poyner and M. Wheatley, Biosci. Rep., 2015, 35, e00188.
12 S. C. Lee, T. J. Knowles, V. L. G. Postis, M. Jamshad, R. A. Parslow, Y.-P. Lin, A. Goldman, P. Sridhar, M. Overduin, S. P. Muench and T. R. Dafforn, Nat. Protoc., 2016, 11, 1149–1162.
13 J. Broeker, B. T. Eger and O. P. Ernst, Structure, 2017, 25, 384–392.
14 C. Sun, S. Benlekbir, P. Venkatakrishnan, Y. Wang, S. Hong, J. Hosler, E. Tajkhorshid, J. L. Rubinstein and R. B. Gennis, Nature, 2018, 557, 123–126.
15 S. J. Briddon, B. Kellam and S. J. Hill, Methods Mol. Biol., 2011, 746, 211–236.
16 L. A. Stoddart, L. E. Kilpatrick, S. J. Briddon and S. J. Hill, Neuphararmacology, 2015, 98, 48–57.
17 L. A. Stoddart, L. E. Kilpatrick and S. J. Hill, Trends Pharmacol. Sci., 2018, 39, 136–147.
18 S. J. Briddon, L. E. Kilpatrick and S. J. Hill, Trends Pharmacol. Sci., 2018, 39, 158–174.
19 U. Meseth, T. Wohland, R. Rigler and H. Vogel, Biophys. J., 1999, 76, 1619–1631.
20 R. Corriden, L. E. Kilpatrick, B. Kellam, S. J. Briddon and S. J. Hill, FASEB J., 2014, 28, 4211–4222.
21 S. J. Briddon, R. J. Middleton, Y. Cordeaux, F. M. Flavin, J. A. Weinstein, M. W. George, B. Kellam and S. J. Hill, Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 4673–4678.
22 L. E. Kilpatrick, S. J. Briddon and N. D. Holliday, Biochim. Biophys. Acta, 2012, 1823, 1068–1081.
23 R. Machan and T. Wohland, FEBS Lett., 2014, 588, 3571–3584.
24 L. E. Kilpatrick and S. J. Hill, Biochem. Soc. Trans., 2016, 44, 624–629.
25 B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, J. Linden and C. E. Müller, Pharmacol. Rev., 2011, 63, 1–34.
26 B. B. Fredholm, J. F. Chen, S. A. Masino and J. M. Vagueois, Annu. Rev. Pharmacol. Toxicol., 2005, 45, 385–412.
27. M. Wachsmuth, C. Conrad, J. Bulkescher, B. Koch, R. Mahen, M. Isokane, R. Pepperkok and J. Ellenberg, *Nat. Biotechnol.*, 2015, 33, 384–389.
28. S. C. L. Hall, C. Tognoloni, J. Charlton, E. C. Bragginton, A. J. Rothnie, P. Sriridhar, M. Wheatley, T. J. Knowles, T. Arnold, K. J. Edler and T. R. Dafforn, *Nanoscale*, 2018, 10, 10609–10619.
29. T. Ravula, N. Z. Hardin, S. K. Ramadugu, S. J. Cox and A. Ramamoorthy, *Angew. Chem., Int. Ed.*, 2018, 57, 1342–1345.
30. A. O. Oluwole, B. Danielczak, A. Meister, J. O. Babalola, C. Vargas and S. Keller, *Angew. Chem., Int. Ed.*, 2017, 56, 1919–1924.
31. C. A. Schneider, W. S. Rasband and K. W. Eliceiri, *Nat. Methods*, 2012, 9, 671–675.
32. Y. Cheng and W. H. Prusoff, *Biochem. Pharmacol.*, 1973, 22, 3099–3108.
33. L. A. Stoddart, A. J. Vernall, J. L. Denman, S. J. Briddon, B. Kellam and S. J. Hill, *Chem. Biol.*, 2012, 19, 1105–1115.
34. A. J. Vernall, L. A. Stoddart, S. J. Briddon, H. W. Ng, C. A. Laughton, S. W. Doughty, S. J. Hill and B. Kellam, *Org. Biomol. Chem.*, 2013, 11, 5673–5682.
35. L. A. Stoddart, E. K. M. Johnstone, A. J. Wheal, J. Goulding, M. B. Roberts, T. Machleidt, K. V. Wood, S. J. Hill and K. D. G. Pfleger, *Nat. Methods*, 2015, 12, 661–663.
36. J. R. Keddie, S. M. Poucher, G. R. Shaw, R. Brooks and M. G. Collis, *Eur. J. Pharmacol.*, 1996, 301, 107–113.
37. S. C. L. Hall, C. Tognoloni, G. J. Price, B. Klumperman, K. J. Edler, T. R. Dafforn and T. Arnold, *Biomacromolecules*, 2018, 19, 761–772.
38. D. Wootten, A. Christopoulos and P. Sexton, *Nat. Rev. Drug Discovery*, 2013, 12, 630–644.
39. T. H. Bayburt and S. G. Slijper, *FEBS Lett.*, 2010, 584, 1721–1727.
40. K. S. Simon, N. L. Pollock and S. C. Lee, *Biochem. Soc. Trans.*, 2018, 46, 1495–1504.
41. J.-M. Swiecicki, J. T. Santana and B. Imperiali, *Cell Chem. Biol.*, 2020, 27, 245–251.
42. A. J. Horsey, D. A. Briggs, N. D. Holliday and S. J. Briddon, *Biochim. Biophys. Acta, Biomembr.*, 2020, 1862, 183218.
43. V. Schmidt and J. N. Sturgis, *Biochim. Biophys. Acta*, *Biomembr.*, 2018, 1860, 777–783.
44. R. Dawaiiby, C. Trubbia, C. Delpoerto, M. Masureel, P. Van Antwerpen, B. K. Kobila and C. Govaerts, *Nat. Chem. Biol.*, 2016, 12, 35–39.
45. S. Muth, A. Fries and G. Gimpl, *Biochem. J.*, 2011, 437, 541–553.
46. G. Gimpl, K. Burger and F. Fahrenholz, *Biochemistry*, 1997, 36, 10959–10974.
47. L. Pang, M. Graziano and S. Wang, *Biochemistry*, 1999, 38, 12003–12011.
48. M. A. Hanson, V. Cherevezov, M. T. Griffith, C. B. Roth, V. P. Jaakola, E. Y. Chien, J. Velasquez, P. Kuhn and R. C. Stevens, *Structure*, 2008, 16, 897–905.
49. H. Y. Yen, K. K. Hoi, I. Liko, G. Hedger, M. R. Horrell, W. Song, D. Wu, P. Heine, T. Warne, Y. Lee, B. Carpenter, A. Plückthun, C. G. Tate, M. S. P. Sansom and C. V. Robinson, *Nature*, 2018, 559, 423–427.
50. S. J. Routledge, M. Jamshad, H. A. Little, Y.-P. Lin, J. Simms, A. Thakker, C. M. Spickett, R. M. Bill, T. R. Dafforn, D. R. Poyner and M. Wheatley, *Biochim. Biophys. Acta, Biomembr.*, 2020, 1862, 183235.
51. G. Hazell, T. Arnold, R. D. Barker, L. A. Clifton, N. J. Steinke, C. Tognoloni and K. J. Edler, *Langmuir*, 2016, 32, 11845–11853.